RRD International Strengthens Scientific Team with Key Appointment Former FDA and Clinical Pharmacology Expert, Jennifer DiGiacinto Joins RRD
ROCKVILLE, Md., Sept. 30, 2013 /PRNewswire/ -- RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced the recent addition of Jennifer DiGiacinto, Pharm.D., to the RRD team. In her role as Senior Technical Advisor, Dr. DiGiacinto will work closely with RRD partner companies to provide strategic direction on clinical pharmacology and regulatory issues related to their development programs.
"The combination of Jennifer's extensive experience in clinical pharmacology, regulatory strategy and FDA perspective adds significant value to RRD's development programs," said RRD President, Scott Tarrant. "Jennifer's expertise brings a key core competency in-house, strengthening the turn-key product development alternative sought by our partners under RRD's Product Development Team (PDT) model."
Dr. DiGiacinto has over 13 years of experience in biopharmaceutics, clinical pharmacology and regulatory affairs. Before joining RRD, she was a Senior Clinical Pharmacologist at Salamandra LLC, providing technical and regulatory advice relating to early stage clinical trials. Prior to that, Dr. DiGiacinto spent 7 years at the US FDA/CDER as a Senior Clinical Pharmacology Reviewer within the Office of Clinical Pharmacology, providing guidance to sponsors on current drug development regulations, policy and procedures. Dr. DiGiacinto earned her Doctor of Pharmacy degree from the University of Nebraska Medical Center, College of Pharmacy. Following graduation she completed her pharmacy residency at University of Nebraska Medical Center Hospital and then completed a two year clinical pharmacology fellowship funded by FDA at University of Illinois Medical Center.
About RRD International:
RRD International is a product development company that provides integrated, expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors. The Company's unique Product Development Team model (PDT) provides an effective, asset-centric alternative to traditional industry practices. While comprehensive in value, structure and function – encompassing all aspects of a development program including strategic planning, management and execution – the PDT model is also highly resource efficient with an intense focus on minimizing cost, time and risk to achieve human proof-of-concept (POC). Since 2002, RRD has worked with more than 100 organizations across all major classes and therapeutic areas. For more information, visit rrdintl.com.
SOURCE RRD International